Shots:
- nChroma Bio has dosed the first patient with CRMA-1001, an epigenetic silencer, in a P-I/II trial for the treatment of hepatitis B virus (HBV) infection
- The open-label study is evaluating the safety, tolerability, PK/PD, & efficacy of CRMA-1001 in adults with CHB across single & multiple-ascending dose cohorts, with enrollment ongoing
- Additionally, the company secured CTA approvals in New Zealand & the UK, building on prior Hong Kong clearance & enabling study initiation while further expanding its global trial footprint
Ref: Businesswire |  Image: nChroma  | Press Release
Related News: Roche Reports Positive P-II Results of Dual GLP-1/GIP Agonist CT-388 in Obesity
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
